INTELLIGENT PEPTIDE DISCOVERY

Unique Artificial Intelligence for groundbreaking drug discovery

WHO WE ARE

Pepticom Ltd. was founded in 2011 to revolutionize the discovery of novel peptide drug candidates. Pepticom’s key asset is an exceptional artificial intelligence platform aimed at designing peptide ligands based upon solved crystal structures. Pepticom operates in various disciplines, generates innovative binding peptides for diverse targets. The main projects involve developing agonists and antagonists for immunology and metabolic disorders. Pepticom is successfully engaged in additional development projects for other indications. Read more about Pepticom Ltd. in the About section.